1. Immunotherapies and novel combinations: the focus of advances in the treatment of melanoma

   • Paolo A. Ascierto

   Commentary 31 December 2014 Pages: 271 - 274

2. Expression and function of Toll-like receptors in peripheral blood mononuclear cells from patients with ovarian cancer

   • Xiaojie Zhang
   • Juan Xu
   • Shiyang Pan

   Original Article 07 November 2014 Pages: 275 - 286

   

3. Development of photodynamic therapy regimens that control primary tumor growth and inhibit secondary disease

   • Madeeha Shams
   • Barbara Owczarczak
   • Sandra O. Gollnick

   Original Article Open access 11 November 2014 Pages: 287 - 297

   

4. Glioblastoma exosomes and IGF-1R/AS-ODN are immunogenic stimuli in a translational research immunotherapy paradigm

   • Larry A. Harshyne
   • Kirsten M. Hooper
   • D. Craig Hooper

   Original Article 14 November 2014 Pages: 299 - 309

   

5. Blockade of CTLA-4 promotes the development of effector CD8⁺ T lymphocytes and the therapeutic effect of vaccination with an attenuated protozoan expressing NY-ESO-1

   • Luara Isabela dos Santos
   • Bruno Galvão-Filho
   • Ricardo Tostes Gazzinelli

   Original Article 18 November 2014 Pages: 311 - 323

   

6. Protection from tumor recurrence following adoptive immunotherapy varies with host conditioning regimen despite initial regression of autochthonous murine brain tumors

   • Eugene M. Cozza
   • Timothy K. Cooper
   • Todd D. Schell

   Original Article 19 November 2014 Pages: 325 - 336

   

7. Activated regulatory and memory T-cells accumulate in malignant ascites from ovarian carcinoma patients

   • Johannes Landskron
   • Øystein Helland
   • Kjetil Taskén

   Original Article 22 November 2014 Pages: 337 - 347

   

8. Fever and the use of paracetamol during IL-2-based immunotherapy in metastatic melanoma

   • Anne Helene Køstner
   • Mai-Britt Bjørklund Ellegaard
   • Henrik Schmidt

   Original Article 02 December 2014 Pages: 349 - 355

   

9. Association of high CD4-positive T cell infiltration with mutations in HLA class II-regulatory genes in microsatellite-unstable colorectal cancer

   • Eva-Maria Surmann
   • Anita Y. Voigt
   • Matthias Kloor

   Original Article 02 December 2014 Pages: 357 - 366

   

10. A phase I dose escalation trial of MAGE-A3- and HPV16-specific peptide immunomodulatory vaccines in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN)

    • Dan P. Zandberg
    • Sandra Rollins
    • Martin J. Edelman

    Original Article 24 December 2014 Pages: 367 - 379

    

11. Long-term clinical outcome of melanoma patients treated with messenger RNA-electroporated dendritic cell therapy following complete resection of metastases

    • Sofie Wilgenhof
    • Jurgen Corthals
    • Bart Neyns

    Original Article 30 December 2014 Pages: 381 - 388

    

12. Tumor-induced CD14⁺HLA-DR^−/low myeloid-derived suppressor cells correlate with tumor progression and outcome of therapy in multiple myeloma patients

    • Zhitao Wang
    • Lulu Zhang
    • Zhimin Zhai

    Original Article 30 December 2014 Pages: 389 - 399